Editas Medicine (EDIT) | Financial Analysis & Statements
Editas Medicine Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
24.7M
Operating Income
-14.0M
-56.65%
Net Income
-5.6M
-22.72%
Balance Sheet Metrics
Total Assets
186.5M
Total Liabilities
159.2M
Shareholders Equity
27.3M
Debt to Equity
5.84
Cash Flow Metrics
Operating Cash Flow
-15.8M
Free Cash Flow
-36.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Editas Medicine Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40.5M | 32.3M | 78.1M | 19.7M | 25.5M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 90.0M | 199.2M | 177.7M | 175.0M | 142.5M |
| Selling, General & Administrative | 49.9M | 72.0M | 69.7M | 70.7M | 76.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 139.9M | 271.2M | 247.3M | 245.7M | 218.7M |
| Operating Income | -99.3M | -238.9M | -169.2M | -226.0M | -193.1M |
| Operating Margin % | -245.2% | -739.4% | -216.6% | -1,146.3% | -756.1% |
| Non-Operating Items | |||||
| Interest Income | 8.3M | 14.1M | 17.6M | 5.5M | 607.0K |
| Interest Expense | 6.2M | - | - | - | - |
| Other Non-Operating Income | -62.9M | -12.2M | -1.6M | 1.3M | 37.0K |
| Pre-tax Income | -160.1M | -237.1M | -153.2M | -220.4M | -192.5M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -160.1M | -237.1M | -153.2M | -220.4M | -192.5M |
| Net Margin % | -395.0% | -733.7% | -196.1% | -1,118.3% | -753.6% |
| Key Metrics | |||||
| EBITDA | -87.9M | -220.9M | -163.1M | -219.6M | -188.1M |
| EPS (Basic) | - | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| EPS (Diluted) | - | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Basic Shares Outstanding | - | 82338220 | 75965633 | 68664822 | 67619388 |
| Diluted Shares Outstanding | - | 82338220 | 75965633 | 68664822 | 67619388 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Editas Medicine Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 146.6M | 131.5M | 123.7M | 141.5M | 203.5M |
| Short-term Investments | 0 | 138.4M | 199.5M | 202.8M | 296.3M |
| Accounts Receivable | 15.2M | 16.3M | 10.2M | 5.1M | 267.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 2.1M | 3.1M | 7.5M | 7.3M | 7.2M |
| Total Current Assets | 163.9M | 289.3M | 340.8M | 356.8M | 507.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 37.7M | 61.7M | 58.7M | 68.1M | 47.8M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.0M | 5.2M | 8.6M | 5.3M | 6.8M |
| Total Non-Current Assets | 22.6M | 52.3M | 158.3M | 157.6M | 170.2M |
| Total Assets | 186.5M | 341.6M | 499.2M | 514.3M | 677.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.6M | 5.5M | 8.3M | 9.5M | 5.0M |
| Short-term Debt | 6.0M | 14.7M | 12.2M | 11.1M | 10.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 46.2M | 77.2M | 63.2M | 60.1M | 46.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 12.1M | 20.4M | 24.4M | 32.9M | 16.1M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 2.8M | 3.1M | 1.8M | - | - |
| Total Non-Current Liabilities | 113.0M | 130.1M | 86.8M | 93.5M | 77.0M |
| Total Liabilities | 159.2M | 207.3M | 150.1M | 153.6M | 123.8M |
| Equity | |||||
| Common Stock | 10.0K | 8.0K | 8.0K | 7.0K | 7.0K |
| Retained Earnings | -1.6B | -1.5B | -1.2B | -1.1B | -857.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 27.3M | 134.3M | 349.1M | 360.7M | 553.6M |
| Key Metrics | |||||
| Total Debt | 18.1M | 35.0M | 36.5M | 43.9M | 26.4M |
| Working Capital | 117.6M | 212.1M | 277.6M | 296.6M | 460.4M |
Balance Sheet Composition
Editas Medicine Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -160.1M | -237.1M | -153.2M | -220.4M | -192.5M |
| Depreciation & Amortization | 5.3M | 5.8M | 6.1M | 6.3M | 5.1M |
| Stock-Based Compensation | 10.0M | 21.4M | 19.8M | 29.3M | 43.4M |
| Working Capital Changes | -19.1M | -12.6M | -5.5M | -2.2M | -21.0M |
| Operating Cash Flow | -158.2M | -220.7M | -131.3M | -187.7M | -163.4M |
| Investing Activities | |||||
| Capital Expenditures | -338.0K | -8.8M | -4.7M | -4.1M | -8.0M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | -86.2M | -258.5M | -315.2M | -408.9M |
| Investment Sales | 139.0M | 257.2M | 259.5M | 433.4M | 362.4M |
| Investing Cash Flow | 138.7M | 162.1M | -3.7M | 114.1M | -54.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 40.0M | 55.2M | 117.1M | 0 | 249.5M |
| Free Cash Flow | -165.8M | -219.1M | -136.9M | -181.5M | -171.8M |
| Net Change in Cash | 20.5M | -3.3M | -17.9M | -73.6M | 31.6M |
Cash Flow Trend
Editas Medicine Key Financial Ratios
Valuation Ratios
Forward P/E
-3.82
Price to Book
11.83
Price to Sales
7.97
PEG Ratio
-3.82
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-56.65%
Return on Equity
-198.14%
Return on Assets
-23.51%
Financial Health
Current Ratio
3.54
Debt to Equity
66.34
Beta
2.04
Per Share Data
EPS (TTM)
$-1.80
Book Value per Share
$0.28
Revenue per Share
$0.46
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| EDIT | 323.0M | - | 11.83 | -198.14% | 0.00% | 66.34 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






